Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Dropbox Inc (DBX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Dropbox Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Dropbox Inc trades at $28.76 (market cap $6.73B). The key difference: Dropbox Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| ACAD | DBX | |
|---|---|---|
Market Cap | $4.49B | $6.73B |
Sector | Health | Technology |
52-Week High | $28.06 | $32.17 |
52-Week Low | $20.06 | $22.06 |
Enterprise Value | $3.69B | $9.45B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
DBX trades at $28.85, up 1.02% today, with a bullish technical signal from moving averages and a consensus price target of $30.00. The company maintains strong profitability with a net income margin of 18.71% and has beaten earnings estimates for three consecutive quarters. Recent developments include a new $900 million stock repurchase program and CEO transition news from Reuters on 2026-05-26.
Outlook remains positive with steady revenue near $2.5 billion and robust cash flow, though risks include high debt levels and competitive pressures. The stock offers moderate upside to the price target with support from buybacks, but investors should monitor execution under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Dropbox Inc
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →
